Kinetics of antibody-antigen binding evaluated by ELISA in refractory cancer patient

Cancer Science & Therapy

ISSN: 1948-5956

Open Access

Kinetics of antibody-antigen binding evaluated by ELISA in refractory cancer patient

32nd Euro Congress on Cancer Science & Therapy

March 07-08, 2019 | Barcelona, Spain

Itzia Xiuhnelly Nava Sanchez, Pedro Alejandro Lucero Diaz, Jose Antonio Matute Briceno, Alejandro Camacho, Juan Pablo Marquez Manriquez and Salvador Icedo Zamora

Sonora Cancer Research Center (CICS), USA

Scientific Tracks Abstracts: J Cancer Sci Ther

Abstract :

Kinetics of antigen binding influence how, potently antibodies attack strong enough tumor cells at the clinical level and contribute in combination with other therapies potentially better outcomes when we induce multiple antigen specific antibodies against multiple clinical relevant targets in progressive and refractory cancer patients with an ECOG=0-1. The potential of immunological assays such as peptide Enzyme-Linked Immuno Sorbent Assay (ELISA) to predict affinity of antibody-antigen are mainly unexplored as many of the studies in cancer either for diagnosis, prognosis, etc. Most of the researchers assume that all the repertoire of antibodies, tumor associated antigens, recall antigens, etc. will behave equally. We decided to analyze by ELISA the kinetics of antigen-antibody binding at one, two, six, twelve, twenty four and seventy two hours without adding stopping solution. The study was retrospective and approved by the local ethic committee. We analyze (n=20) the kinetics of antibody-antigen reactions using clinically relevant immunogenic peptides such as RCAS1-A, VCP-4, SURVIVIN-A, Fascin-1, EGFR-D, Bcl2-A, SOX2-B and APE1-A in refractory cancer patients as following with breast cancer (n=2), pancreatic cancer (n=1), sarcoma (n=3), prostate cancer (n=2), ovarian cancer (n=1) and colorectal and colon cancer (n=1) and presumably healthy patients (n=10). With this proof of principle, the procedure was changed, adding the first antibody of each patient (serum dilution 1:200) and were incubated for 2 and 24 hours according with our preliminary results. We found statistical differences between different types of tumors, epitopes and two and twenty four hourÔ??s kinetics. As preliminary conclusion, exposing the antigen-antibody interaction in two and twenty-four hours process in different subtypes of cancer, putatively predict the specific immune system behavior and the increase in titles in the reaction of an specific peptide at 24 hours might translate into greater maturity and memory of the immune system. However, an increased number of samples will be useful to clarify possible clinical associations.

Biography :

Itzia Xiuhnelly Nava Sanchez is a Medical Doctor with training at La Salle University, Victoria and Escandon Hospital in Mexico City. Currently, she is a Medical Doctor and Investigator of the Binational Sonora Cancer Research Center (CICS) in Seattle/Sonora. She has also performed clinical experience, providing medical attention to patients who enter to cancer prevention protocol, carrying out clinical history, physical exploration, orientation about primary, secondary and tertiary prevention according to the age and comorbidities of patients, obtaining blood samples and subsequently analyzing the results. In the research area, she attends the development of scientific projects with clinic relevance and performed experiments focused on patient's immune response against cancer. She is a Member of ASCO and ESMO. She has been involved in some published scientific articles of the OMA/CICS group and aspires to subsequently specialize in the area of pediatric oncology.



Google Scholar citation report
Citations: 3771

Cancer Science & Therapy received 3771 citations as per Google Scholar report

Cancer Science & Therapy peer review process verified at publons

Indexed In

arrow_upward arrow_upward